Update on medical treatment of patients with eisenmenger syndrome

Hiroyuki Fukushima

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension (PAH) associated with congenital heart defects. ES greatly affects functional capacity, quality of life, and survival of patients. Clinical management of patients with ES has been dramatically changed and developed in a new therapeutic era of PAH, approximately a century after the first ES case described by Dr. Eisenmenger. Targeted drugs for PAH improve functional capacity and quality of life of patients with ES. In addition, these drugs may also provide a benefit for patients' survival. To achieve further development in medical treatment of patients with ES, they will need to be individualized according to functional classes, underlying cardiac defects, and underlying systemic diseases.

Original languageEnglish
Pages (from-to)S4-S7
JournalInternational Heart Journal
Volume56
DOIs
Publication statusPublished - 2015

Fingerprint

Eisenmenger Complex
Pulmonary Hypertension
Therapeutics
Quality of Life
Survival
Congenital Heart Defects
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Update on medical treatment of patients with eisenmenger syndrome. / Fukushima, Hiroyuki.

In: International Heart Journal, Vol. 56, 2015, p. S4-S7.

Research output: Contribution to journalArticle

@article{62239bb6b382456491fb11747d7bbc19,
title = "Update on medical treatment of patients with eisenmenger syndrome",
abstract = "Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension (PAH) associated with congenital heart defects. ES greatly affects functional capacity, quality of life, and survival of patients. Clinical management of patients with ES has been dramatically changed and developed in a new therapeutic era of PAH, approximately a century after the first ES case described by Dr. Eisenmenger. Targeted drugs for PAH improve functional capacity and quality of life of patients with ES. In addition, these drugs may also provide a benefit for patients' survival. To achieve further development in medical treatment of patients with ES, they will need to be individualized according to functional classes, underlying cardiac defects, and underlying systemic diseases.",
author = "Hiroyuki Fukushima",
year = "2015",
doi = "10.1536/ihj.14-347",
language = "English",
volume = "56",
pages = "S4--S7",
journal = "International Heart Journal",
issn = "1349-2365",
publisher = "International Heart Journal Association",

}

TY - JOUR

T1 - Update on medical treatment of patients with eisenmenger syndrome

AU - Fukushima, Hiroyuki

PY - 2015

Y1 - 2015

N2 - Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension (PAH) associated with congenital heart defects. ES greatly affects functional capacity, quality of life, and survival of patients. Clinical management of patients with ES has been dramatically changed and developed in a new therapeutic era of PAH, approximately a century after the first ES case described by Dr. Eisenmenger. Targeted drugs for PAH improve functional capacity and quality of life of patients with ES. In addition, these drugs may also provide a benefit for patients' survival. To achieve further development in medical treatment of patients with ES, they will need to be individualized according to functional classes, underlying cardiac defects, and underlying systemic diseases.

AB - Eisenmenger syndrome (ES) is the most advanced form of pulmonary arterial hypertension (PAH) associated with congenital heart defects. ES greatly affects functional capacity, quality of life, and survival of patients. Clinical management of patients with ES has been dramatically changed and developed in a new therapeutic era of PAH, approximately a century after the first ES case described by Dr. Eisenmenger. Targeted drugs for PAH improve functional capacity and quality of life of patients with ES. In addition, these drugs may also provide a benefit for patients' survival. To achieve further development in medical treatment of patients with ES, they will need to be individualized according to functional classes, underlying cardiac defects, and underlying systemic diseases.

UR - http://www.scopus.com/inward/record.url?scp=84929942740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929942740&partnerID=8YFLogxK

U2 - 10.1536/ihj.14-347

DO - 10.1536/ihj.14-347

M3 - Article

VL - 56

SP - S4-S7

JO - International Heart Journal

JF - International Heart Journal

SN - 1349-2365

ER -